nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

07.01.2016 | Case Report

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

verfasst von: Saranya Kodali, Venu Bathini, Paul Rava, Eswar Tipirneni

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Colorectal cancer is the third most common cancer and second leading cause of cancer-related death in the United States [1]. Fluoropyrimidines are the back bones of systemic chemotherapy in colorectal cancer. Currently, two forms of fluoropyrimidines, an intravenous 5-fluorouracil (5-FU) and its oral prodrug capecitabine, are widely used in the western world. Nearly 1/3 of patients with colorectal malignancies experience grade 3 or greater toxicities associated with the use of fluoropyrimidines, and treatment-related mortality rate approaches 0.5 % [2]. …

Colorectal Cancer Screening and Surveillance—American Family Physician. Accessed March 11, 2015. http://www.aafp.org/afp/2015/0115/p93.html.

Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939–50. doi:10.1016/j.ejca.2003.12.004.CrossRefPubMed

Van Kuilenburg ABP, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D, et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14 + 1G> a mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids. 2008;27(6–7):692–8. doi:10.1080/15257770802145009.CrossRefPubMed

Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4(3):181–9. doi:10.3816/CCC.2004.n.018.CrossRefPubMed

Blasco H, Boisdron-Celle M, Bougnoux P, Gilles C, Tournamille J-F, Ciccolini J, et al. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol. 2008;65(6):966–70. doi:10.1111/j.1365-2125.2008.03106.x.CrossRefPubMedPubMedCentral

Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer J-C, Richard K, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272–5. doi:10.1007/s00280-005-0139-8.CrossRefPubMed

Van Kuilenburg ABP, Vreken P, Abeling NGGM, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104(1):1–9. doi:10.1007/PL00008711.CrossRefPubMed

Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer. 2006;6(4):288–96. doi:10.3816/CCC.2006.n.047.CrossRefPubMed

van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705–12.PubMed

10.

Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249(2):271–82. doi:10.1016/j.canlet.2006.09.006.CrossRefPubMed

11.

Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D’Amico M, et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol. 2011;68(5):1355–61. doi:10.1007/s00280-011-1709-6.CrossRefPubMed

12.

Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer J-C, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28(5):678–85. doi:10.1097/01.ftd.0000245771.82720.c7.CrossRefPubMed

13.

National Guideline Clearinghouse/Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Accessed March 11, 2015. http://www.guideline.gov/content.aspx?id=47994.

14.

Magnani E, Farnetti E, Davide N, Casali B, Savoldi L, Focaccetti C, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417–23. doi:10.1007/s11739-013-0936-8.CrossRefPubMed

15.

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2015. doi:10.1200/JCO.2015.63.1325.

16.

Barni S, Ghidini A, Coinu A, Borgonovo K, Petrelli F. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anticancer Drugs. 2014;25(10):1122–8. doi:10.1097/CAD.0000000000000133. Review.CrossRefPubMed

Titel: Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil
verfasst von: Saranya Kodali
Venu Bathini
Paul Rava
Eswar Tipirneni
Publikationsdatum: 07.01.2016
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-015-9797-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Free/Total Serum Prostate-Specific Antigen Ratio in Women with Colorectal Cancer Has Prognostic Significance

Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus

A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy

Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus—Reducing the Colostomy Rate

Bile Duct Hamartoma Mimicking Metastatic Cholangiocarcinoma

Laparoscopic Versus Open Resection for Gastrointestinal Stromal Tumors (GISTs)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie